This week in Drug Discovery (21-25 September 2026)
News round-up for 21-25 September 2026 by Megan Thomas, Content Team at DDW.
This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Digital Forum and the Drug Discovery Innovators & Investors Conference in London, as well as the latest developments in drug discovery, including clinical trial setbacks, investment and collaboration, AI-driven drug discovery, and Parkinson’s research funding.
The top stories:
Last chance: Register for the Drug Discovery Innovators & Investors Digital Forum
Join us on 30 September for the Drug Discovery Innovators & Investors Digital Forum, covering topics such as early-stage drug discovery collaboration, lab efficiency, breakthrough therapies, and capital flow.
View the agenda and register now…
Novartis faces September’s fourth trial disappointment with ALS drug
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases.
Six reasons to register for Drug Discovery Innovators & Investors UK Conference
Early bird rates for the Drug Discovery Innovators & Investors (DDII) UK Conference close on 30 September 2026. Taking place on 4 November 2026 at etc.venues Monument in London, UK, the conference brings together pharma and biotech companies, technology suppliers, academia, start-ups, spin-outs and investors for a focused day of insight, collaboration and networking.
New deals boost Novo Nordisk’s AI drug discovery ambitions
Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases.
Grants support research into sleep mechanisms in Parkinson’s
AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL).
